The findings come from a meta-analysis of 42 trials, involving almost 18,000 patients aged an average of 56 years.
It also showed that the risk of death from all cardiovascular causes was 63 per cent higher in patients given rosiglitazone, compared with those given drug regimens excluding rosiglitazone.
Until more precise estimates of the risks of this treatment on cardiovascular health were carried out, providers should give 'careful consideration to the risks and benefits of their overall treatment plans', according to the researchers from the Cleveland Clinic in Ohio.
A spokeswoman for the MHRA said product information for rosiglitazone always had warnings on this risk and was updated by the European Medicines Agency in 2006. She added the safety of Avandia was being kept under review.What do you think? Comment below or email us at GPletters@haymarket.com